Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Regeneron Pharmaceuticals Inc. (REGN)股价已触及52周低点，交易价格为785.31美元。这一价格水平反映出过去一年来股价出现了0.43%的微小但显著下跌，表明这家以创新药物闻名的生物技术公司正处于整固期。投资者正密切关注该股在这一低点的表现，考虑公司的业绩以及可能影响未来几个月走势的潜在市场动向。 在其他近期新闻中，Regeneron Pharmaceutica ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...

你有没有想过，一家制药公司的股价波动，背后可能隐藏着什么样的故事呢？今天我们就来聊聊再生元制药（Regeneron Pharmaceuticals）的股价下跌，看看这背后究竟发生了什么。 最近，再生元制药的股价在盘中下跌了1.25%，报833.05美元/股。这样的跌幅虽然不算特别大，但足以引起投资者和市场的关注。那么，是什么原因导致了这次股价的下跌呢？ 首先，我们来看看再生元制药的基本面。根据最新 ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...